LETROZOLE ZENTIVA 2.5mg x 30 tabl
•Adjuvant therapy in postmenopausal women with hormone receptor-positive early invasive breast cancer. •Extended adjuvant therapy of hormone receptor-positive invasive breast cancer in postmenopausal women who have previously been treated with tamoxifen as standard adjuvant therapy for 5 years. •First-line therapy in postmenopausal women with hormone receptor-positive advanced breast cancer. •Treatment of advanced breast cancer after recurrence or progression of disease in women with natural or artificially induced postmenopausal endocrine status who have previously been treated with antiestrogens. •Neoadjuvant therapy in postmenopausal women with hormone receptor-positive, HER-2 negative breast cancer in whom chemotherapy is not appropriate and immediate surgery is not indicated. Efficacy has not been demonstrated in patients with hormone receptor-negative breast cancer. Letrozole
